Michael Cerio

Michael Cerio has a diverse and extensive work experience in the biotechnology and pharmaceutical industries. Michael is currently the Vice President of BioPharma at SOPHiA GENETICS, where they focus on strategic partnerships with pharma and biotech companies in the data science and digital health field. Their work involves applying artificial intelligence and next-generation sequencing to develop new therapeutic approaches for oncology, rare diseases, and other areas of unmet medical needs.

Before their current role, Michael worked as a consultant in diagnostics, lab services, biomarkers, and spatial omics. Prior to that, they served as the Chief Commercial Officer at StageBio, a company specializing in preclinical and clinical pathology services.

Michael has held several leadership positions at Biocare Medical, including President of Laboratory Services and Molecular Diagnostics. In this role, they led the development of companion diagnostic tests, biomarker assays, and clinical trial testing for pharmaceutical partners. Michael also served as the Chief Business Officer, responsible for marketing, pharmaceutical partnerships, academic collaborations, licensing, IP strategy, and alliance management.

Earlier in their career, Michael held positions at Signal Genetics, Inc., where they served as the Chief Commercial Officer and Senior Vice President of Commercial Strategy and Business Development. Michael was also a consulting CEO at Modulation Therapeutics and served as the President and CEO of Oncolome Diagnostics.

Michael's experience includes roles in business development at Genzyme, BG Medicine, and Genaissance Pharmaceuticals, where they played a key role in building strategic partnerships and driving growth.

Overall, Michael Cerio brings a wealth of experience and expertise in strategic partnering, commercialization, and business development to the biotechnology and pharmaceutical industries.

Michael Cerio completed a Master of Business Administration (M.B.A.) degree from Columbia Business School in an unspecified year prior to 2003. Before that, they obtained a Master of Science (M.S.) degree in Cellular and Molecular Biology from the University of Connecticut, finishing their studies in 1997. Their education journey began at Syracuse University, where they earned a Bachelor of Science (B.S.) degree in Biology in 1993.